Arcus Biosciences (RCUS) Operating Expenses (2017 - 2026)

Arcus Biosciences' Operating Expenses history runs 10 years deep, the most recent figure standing at $151.0 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 0.67% year-over-year to $151.0 million; the TTM figure through Mar 2026 stood at $634.0 million (up 9.88% YoY), while the FY2025 annual figure was $633.0 million, up 7.65% from the prior year.
• Operating Expenses was $151.0 million for Q1 2026 at Arcus Biosciences, up from $147.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $168.0 million in Q2 2025 to a low of $85.0 million in Q1 2022.
• Historically, Operating Expenses has averaged $130.6 million across 5 years, with a median of $129.0 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses soared 46.74% in 2022, then fell 6.83% in 2025.
• A 5-year view of Operating Expenses shows it stood at $108.0 million in 2022, then advanced by 12.96% to $122.0 million in 2023, then grew by 5.74% to $129.0 million in 2024, then increased by 13.95% to $147.0 million in 2025, then advanced by 2.72% to $151.0 million in 2026.
• The last three Operating Expenses figures came in at $151.0 million (Q1 2026), $147.0 million (Q4 2025), and $168.0 million (Q3 2025), per Business Quant data.